← FDA DRUG APPROVALS

FDA ANDA · ANDA074617

DILTIAZEM HYDROCHLORIDE

Sponsor: SAGENT

APPLICATION
ANDA074617
TYPE
ANDA
ORIGINAL APPROVAL
1996-02-28
LATEST ACTION
2001-04-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DILTIAZEM HYDROCHLORIDEPrescription
DILTIAZEM HYDROCHLORIDE 5MG/ML · INJECTABLE · INJECTION

Approval history

2001-04-03Manufacturing (CMC) · Supplement 10AP
2000-06-28Manufacturing (CMC) · Supplement 8AP
2000-04-12Labeling · Supplement 9AP
2000-03-30Labeling · Supplement 4AP
2000-03-30Manufacturing (CMC) · Supplement 7AP
2000-03-30Manufacturing (CMC) · Supplement 5AP
2000-03-30Manufacturing (CMC) · Supplement 3AP
2000-03-30Manufacturing (CMC) · Supplement 6AP
1997-04-29Manufacturing (CMC) · Supplement 2AP
1996-09-27Labeling · Supplement 1AP
1996-02-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →